GENKYOTEX INNOVATION SAS (GKT) is a French company founded in 2011. It is wholly owned by GenKyoTex SA (www.genkyotex.com), a Swiss company founded in 2006 and the world leader in the development of NADPH oxidases (NOX) inhibitors. GenKyoTex develops targeted anti-oxidative therapy by blocking specifically the source of reactive oxygen species (ROS). GenKyoTex has a unique battery of assays for discovery and screening of small molecules targeting different NOX isoforms and medicinal chemistry expertise which has resulted in the filing of 9 patents covering different series of small molecule inhibitors of the NOX enzymes. The lead molecule , GKT137831, is a 1st in class dual NOX 1 / 4 inhibitor which entered clinical Phase 1 testing in October 2011 and is initially targeted for the treatment of diabetic nephropathy. Genkyotex has 14 employees involved in medicinal chemistry, biotechnology, screening, in vivo pharmacology, as well as clinical development. The role of GKT in the NEURINOX project is to identify small molecules NOX inhibitors, which can be targeted specifically for use in the treatment of Neurodegenerative diseases.
Role in the Project
Freddy Heitz is head of Screening and Biotechnology at Genkyotex. He took his PhD in pharmacology and molecular biology from University Louis Pasteur Strasbourg in 1996. He joined GenKyoTex in 2008 and is responsible for the development of the unique Genkyotex Nox screening platform. He has more than 15 years of pharmaceutical industry experience and a strong knowledge of the drug discovery process.
Benoît Laleu, Scientist I holds a PhD in Chemistry from the University of Geneva (2006). He did a post-doctoral research fellowship with Prof. Mark Lautens (U. of Toronto, Canada). He is co-author of 12 research publications and co-inventor of 4 patents.